Solid Phase-Based Cross-Matching as Solution for Kidney Allograft Recipients Pretreated with Therapeutic Antibodies

Table 1

Comparison of the outcome of CDC-based cross-matching with ELISA-based cross-matching (AMS- or AbCross-ELISA, resp.) as shown for twenty-seven patients treated with anti-CD20 mAb Rituximab and four patients treated with anti-CD25 mAb Basiliximab (Simulect).

Patient’s number	CDC-CM (NIH-score)			ELISA-CM		Antibody detection/specification (PRA max.)
	PBL	T-cell	B-cell	Class I	Class II
Rituximab (anti-CD20) [AB0-incompatible living kidney donations]; pretransplant
(1)	2	1/2	6/8	neg.	neg.	PRA = 0%
(2)	2	1	6	neg.	neg.	PRA = 0%
(3)	2/4	1/2	8	neg.	neg.	PRA = 0%
(4)	2	1/2	6/8	neg.	neg.	PRA = 0%
(5)	2/4	2	8	neg.	neg.	PRA = 0%
(6)	2	1/2	8	neg.	neg.	PRA = 0%
(7)	2/4	1/2	8	neg.	neg.	PRA = 0%
(8)	2	1/2	6/8	neg.	neg.	PRA = 0%
(9)	2	1/2	8	neg.	neg.	PRA = 0%
(10)	2/4	2	8	neg.	neg.	PRA = 18%^#
(11)	2	1/2	6/8	neg.	neg.	PRA = 0%
(12)	2	1/2	6	neg.	neg.	PRA = 0%
(13)	2/4	2	8	neg.	neg.	PRA = 0%
(14)	2	1/2	6/8	neg.	neg.	PRA = 0%
(15)	2	1/2	8	neg.	neg.	PRA = 4%^#
(16)	2	1	8	neg.	neg.	PRA = 0%
(17)	2	1/2	6/8	neg.	neg.	PRA = 0%
(18)	2	1	8	neg.	neg.	PRA = 0%
(19)	2/4	1/2	8	neg.	neg.	PRA = 12%^#
(20)	2/4	2	6/8	neg.	neg.	PRA = 0%
(21)	2	1/2	8	neg.	neg.	PRA = 0%
(22)	2/4	2	8	neg.	neg.	PRA = 0%
(23)	2/4	1/2	6/8	neg.	neg.	PRA = 0%
(24)	2	1	6/8	neg.	neg.	PRA = 0%
(25)	2/4	2	8	neg.	neg.	PRA = 0%
(26)	2	1/2	8	neg.	neg.	PRA = 0%
(27)	2	1/2	6/8	neg.	neg.	PRA = 0%
Basiliximab (anti-CD25); posttransplant diagnostics of living kidney donations
(1)	2/4	2/4	4	neg.	neg.	PRA = 0%
(2)	2/4	2/4	4/6	neg.	neg.	PRA = 86%^#
(3)	4	4	6	neg.	pos.	PRA = 12%^&
(4)	6	4	6/8	neg.	pos.	PRA = 20%^&

The outcomes of CDC-based and ELISA-based cross-matching are compared by showing the respective NIH-scores (introduced in Section 2.2) and the corresponding ELISA-based results (introduced in Section 2.2). Additionally, the maximal level of panel reactive antibodies [PRA max.] (introduced in Section 2.3) of each patient is indicated exhibiting the highest historical individual level of immunization against HLA-antigens of the quarterly antibody screening runs. ^#No donor-specific antibodies were identifiable by virtual cross-matching using the Luminex- or DynaChip specifications in spite of the general preimmunization (positive PRA-value); ^&donor-specific anti-HLA class II antibodies were identifiable by virtual cross-matching using Luminex- or DynaChip specifications.